Glucagon-Like Peptide 1 (7-36) Amide (CAS 107444-51-9)

Glucagon-Like Peptide 1 (GLP-1) (7-36) Amide, a peptide hormone produced in the intestine and released in response to food intake, has emerged as a key player in scientific research, particularly within the fields of endocrinology, metabolism, and diabetes. Upon secretion, GLP-1 (7-36) amide binds to GLP-1 receptors located on pancreatic β-cells, resulting in the activation of adenylate cyclase and subsequent elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. This signaling cascade leads to enhanced insulin secretion and synthesis, as well as inhibition of glucagon release, thereby promoting glucose-dependent insulin secretion and lowering blood glucose levels. Additionally, GLP-1 (7-36) amide exerts extrapancreatic effects, including slowing gastric emptying, reducing appetite, and promoting satiety, which contribute to its metabolic benefits. Research utilizing GLP-1 (7-36) amide and its analogs has provided insights into its mechanisms of action and its potential applications for type 2 diabetes mellitus, obesity, and metabolic syndrome. Furthermore, GLP-1 (7-36) amide has been studied for its neuroprotective effects and its implications in neurodegenerative diseases, highlighting its multifaceted roles in metabolic regulation and beyond.